TSS
ANIP icon

Two Sigma Securities’s ANI Pharmaceuticals ANIP Stock Holding History

Two Sigma Securities’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,837
Closed -$233K – 884
2016
Q4 		$233K Sell
3,837
-790
-17% -$48.3K 0.08% 355
2016
Q3 		$307K Buy
+4,627
New +$289K 0.1% 284

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Securities's ANIP Position: Q1 2017 in Review

Two Sigma Securities sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 3,837 shares — an estimated $233K sold.

Two Sigma Securities first reported a position in ANIP in Q3 2016 and held it in 2 quarters. The position peaked at $307K in Q3 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Two Sigma Securities reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Two Sigma Securities sold 3,837 ANI Pharmaceuticals shares in Q1 2017, an estimated $233K.
  • Two Sigma Securities first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Two Sigma Securities's ANI Pharmaceuticals position peaked at $307K in Q3 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Two Sigma Securities's 13F filing for Q1 2017, filed 15 May 2017.